Streetbeat News

Stock Prices

LAKE

Lakeland Industries Inc (NASDAQ:LAKE) reported Q4 FY24 sales of $31.20 million, below the analyst consensus of $32.50 million, with a 7.7% Y/Y growth. Gross profit rose 3.2% Y/Y to $11.2 million, but gross margin fell to 35.9% from 37.5%. The company experienced an operating loss of $3.3 million, a downturn from last year's $0.1 million profit. Adjusted EBITDA improved to $3.4 million from $1.9 million. EPS was $(0.13), missing the $0.30 estimate. Lakeland forecasts FY25 revenue of $140 million to $150 million and adjusted EBITDA of $16.8 million to $18.5 million. Shares closed up 1.44% at $17.67.

Portfolio Pulse from Shivani Kumaresan

April 11, 2024 | 12:12 pm

XTKG

X3 Holdings Co., Ltd. (NASDAQ:XTKG) received a Nasdaq notification for not meeting the minimum bid price requirement. The company's shares have been below $1.00 for over 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). X3 Holdings has until October 7, 2024, to regain compliance by ensuring its share price is at least $1.00 for 10 consecutive trading days. The company plans to take measures to improve its financial position and trading price to address this issue.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:11 pm

TZOO

In Thursday's pre-market session, several communication services stocks showed notable movements. Gainers included So-Young Intl, Travelzoo, FingerMotion, Mobile Global Esports, HWH International, and MediaCo Holding, with increases ranging from 5.03% to 8.8%. Conversely, Weibo, Gaxos.AI, Gamer Pakistan, Outbrain, Hello Gr, and Global Mofy Metaverse experienced declines between 3.88% and 6.5%.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 12:11 pm

ALPN

APVO

ELYM

RLYB

In Thursday's pre-market session, several healthcare stocks showed significant movement. Eliem Therapeutics, Rallybio, and Alpine Immune Sciences were among the top gainers, with stock prices increasing by 51.6%, 49.07%, and 36.62% respectively. On the downside, Aptevo Therapeutics led the losers with a 55.0% decline in its stock price. Other notable decliners include SILO Pharma and Acorda Therapeutics.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 12:11 pm

CSTE

EFOI

FAST

XOS

In Thursday's pre-market session, several industrials stocks showed notable movements. Energy Focus, Xos, and Babcock & Wilcox were among the top gainers, with increases of 21.9%, 12.27%, and 12.03% respectively. On the losing side, Caesarstone, NeoVolta, and Simpple experienced declines of 10.6%, 8.52%, and 5.82% respectively. Fastenal also reported a decrease of 5.01% following its Q1 earnings release.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 12:10 pm

CLRO

HEAR

OST

VERB

In Thursday's pre-market session, 12 Information Technology stocks showed significant movement. Notably, Verb Tech, Ostin Technology Group, and VIA optronics were among the top gainers, while ClearOne, UTime, and Turtle Beach led the losers. The movements reflect changes in market valuations, with companies like BitFuFu showing an 11.49% increase and ClearOne experiencing a 24.5% decrease.

Portfolio Pulse from Benzinga Insights

April 11, 2024 | 12:10 pm

PGR

Progressive's stock price increased following Morgan Stanley's decision to maintain an Overweight rating and raise its price target from $228 to $247.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:09 pm

TEAM

Atlassian's stock (TEAM) experienced a rise following an upgrade by Barclays from Equal-Weight to Overweight, with a new price target set from $235 to $275.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:08 pm

MEIP

MEI Pharma, Inc. (NASDAQ:MEIP) has decided to focus on advancing voruciclib and developing a new formulation of ME-344 based on positive clinical data, foregoing a second capital return under the 2023 Anson and Cable Car Cooperation Agreement to conserve capital. The strategic plan aims to optimize the development of voruciclib for a Phase 3 study in combination with venetoclax for treating relapsed/refractory AML and to enhance ME-344's formulation for treating solid tumors in combination with VEGF inhibitors like Avastin. This decision is aligned with the company's goal to address significant medical needs while managing resources effectively.

Portfolio Pulse from Benzinga Newsdesk

April 11, 2024 | 12:06 pm

FBTC

GBTC

IBIT

Bitcoin spot ETFs experienced a significant net inflow of $123 million, with Fidelity's FBTC and BlackRock's IBIT leading the gains. In contrast, Grayscale's GBTC saw a net outflow of $17.47 million. This movement indicates a shift in investor sentiment towards Bitcoin ETFs, especially ahead of the Bitcoin halving event. Grayscale's CEO suggests that the slowdown in outflows could be due to the resolution of selling pressures from bankrupt crypto companies.

Portfolio Pulse from Murtuza Merchant

April 11, 2024 | 12:05 pm